Congenital Hyperinsulinism
22
3
5
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
4.5%
1 terminated out of 22 trials
92.3%
+5.8% vs benchmark
27%
6 trials in Phase 3/4
67%
8 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (22)
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
18F-DOPA II - PET Imaging Optimization
RZ358 Treatment for Congenital Hyperinsulinism
An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy
A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism
Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
Pasireotide in Hyperinsulinemic Hypoglycemia
Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia
Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
GLP-1 Receptor Expression in CHI
Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism